use of tyrosine kinase recipient agonist To molecule for hematopoietic stem cell amplification protocol and transplantation therapy, and tyrosine kinase recipient agonist of the kit

摘要

The present invention tyrosine kinase recipient (RET), transmembrane tyrosine kinase recipient, hematopoietic stem cells ( HSC) for the agonist molecule of amplification protocol, and relates to the use of HSC transplantation medicine. RET signaling molecules are expressed by HSCs, Ret stripping leads to a reduction in the number of HSC. RET signal, classification survive the queue and ambiguous Bcl2 and Bcl2l1, and downstream of the p38 / MAP kinase, and CREB activity, provide the HSCs. Therefore, forced expression of RET downstream target, Bcl2 or Bcl2l1 is insufficient to restore the activity of the Ret null precursor in vivo. Significantly, the activity of RET is a HSC survival or maintenance, in vivo implantation efficiency and improve, discloses a novel idea for use RET agonists at HSC proliferation and transplantation protocols. Accordingly, the present disclosure is used for HSC amplification protocol and a graft, showing a kit comprising the RET agonist molecules.BACKGROUND